JPWO2020072324A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072324A5 JPWO2020072324A5 JP2021542068A JP2021542068A JPWO2020072324A5 JP WO2020072324 A5 JPWO2020072324 A5 JP WO2020072324A5 JP 2021542068 A JP2021542068 A JP 2021542068A JP 2021542068 A JP2021542068 A JP 2021542068A JP WO2020072324 A5 JPWO2020072324 A5 JP WO2020072324A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- lipid
- compound
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002632 lipids Chemical class 0.000 claims 18
- 239000002245 particle Substances 0.000 claims 11
- -1 poly(oxazoline) Polymers 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 229930182558 Sterol Natural products 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023193747A JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739548P | 2018-10-01 | 2018-10-01 | |
| US62/739,548 | 2018-10-01 | ||
| PCT/US2019/053617 WO2020072324A1 (en) | 2018-10-01 | 2019-09-27 | Biodegradable lipids for the delivery of active agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193747A Division JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508511A JP2022508511A (ja) | 2022-01-19 |
| JPWO2020072324A5 true JPWO2020072324A5 (enExample) | 2022-08-01 |
| JP7387745B2 JP7387745B2 (ja) | 2023-11-28 |
Family
ID=68281954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542068A Active JP7387745B2 (ja) | 2018-10-01 | 2019-09-27 | 活性物質の送達のための生分解性脂質 |
| JP2023193747A Active JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193747A Active JP7747712B2 (ja) | 2018-10-01 | 2023-11-14 | 活性物質の送達のための生分解性脂質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220370356A1 (enExample) |
| EP (3) | EP3860561B1 (enExample) |
| JP (2) | JP7387745B2 (enExample) |
| CN (2) | CN118307422A (enExample) |
| AU (2) | AU2019351809C1 (enExample) |
| CA (1) | CA3114435A1 (enExample) |
| DK (2) | DK4218722T3 (enExample) |
| ES (2) | ES2951836T3 (enExample) |
| WO (1) | WO2020072324A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3842412B1 (en) * | 2018-08-21 | 2024-04-24 | Kabushiki Kaisha Toshiba | Biodegradable lipids for delivery of active compounds into tumor cells comprising two or more tertiary amino groups |
| JP7387745B2 (ja) * | 2018-10-01 | 2023-11-28 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性物質の送達のための生分解性脂質 |
| NZ781026A (en) * | 2019-04-25 | 2025-07-25 | Intellia Therapeutics Inc | Ionizable amine lipids and lipid nanoparticles |
| US20240050378A1 (en) * | 2020-12-02 | 2024-02-15 | Merck Sharp & Dohme Llc | Lipid nanoparticle compositions containing monoester cationic lipids |
| US20240116862A1 (en) * | 2021-01-19 | 2024-04-11 | The University Of British Columbia | Sulfur-containing lipids |
| CN115010681A (zh) * | 2021-09-07 | 2022-09-06 | 安徽荣灿生物科技有限公司 | 一类阳离子脂质体分子及其制备和应用 |
| CN115894281B (zh) * | 2021-09-22 | 2025-07-01 | 广州谷森制药有限公司 | 阳离子脂质化合物、其制备方法、组合物及应用 |
| AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| CN114409554A (zh) * | 2022-01-27 | 2022-04-29 | 英维沃生物科技(苏州)有限公司 | 一种新型阳离子脂质化合物及其组合物和用途 |
| CA3255116A1 (en) | 2022-04-01 | 2023-10-05 | Nanovation Therapeutics Inc | METHOD FOR ADMINISTRATING RNA AND ASSOCIATED COMPOSITION |
| CN117003808A (zh) * | 2022-04-28 | 2023-11-07 | 北京科兴中维生物技术有限公司 | 一种阳离子脂质化合物及其制备方法和用途 |
| CN117243922A (zh) * | 2022-04-29 | 2023-12-19 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒 |
| CN116969851A (zh) | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| CA3266203A1 (en) * | 2022-10-25 | 2024-05-02 | Nanovation Therapeutics Inc | LIPID NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES |
| EP4646213A1 (en) * | 2023-01-06 | 2025-11-12 | Arrowhead Pharmaceuticals, Inc. | Lipid conjugates for the delivery of therapeutic agents to adipose tissue |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| US20110117125A1 (en) | 2008-01-02 | 2011-05-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for the delivery of nucleic acids |
| US8058069B2 (en) * | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| WO2010042877A1 (en) | 2008-10-09 | 2010-04-15 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
| CN105152939A (zh) | 2008-11-10 | 2015-12-16 | 阿尔尼拉姆医药品有限公司 | 用于递送治疗剂的脂质和组合物 |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| KR20210031549A (ko) | 2009-05-05 | 2021-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| KR20230098713A (ko) * | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP2506879A4 (en) | 2009-12-01 | 2014-03-19 | Protiva Biotherapeutics Inc | PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS |
| US20110313017A1 (en) | 2010-01-13 | 2011-12-22 | Protiva Biotherapeutics, Inc. | Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates |
| NZ605079A (en) * | 2010-06-03 | 2015-08-28 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| JP6305343B2 (ja) | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質 |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| CA2856742A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013116126A1 (en) * | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| AU2013249548A1 (en) * | 2012-04-19 | 2014-11-06 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| CA2891911C (en) * | 2012-12-07 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| JP6620093B2 (ja) * | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| JP7387745B2 (ja) * | 2018-10-01 | 2023-11-28 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性物質の送達のための生分解性脂質 |
-
2019
- 2019-09-27 JP JP2021542068A patent/JP7387745B2/ja active Active
- 2019-09-27 DK DK23157471.6T patent/DK4218722T3/da active
- 2019-09-27 EP EP19789841.4A patent/EP3860561B1/en active Active
- 2019-09-27 ES ES19789841T patent/ES2951836T3/es active Active
- 2019-09-27 EP EP23157471.6A patent/EP4218722B1/en active Active
- 2019-09-27 EP EP25196729.5A patent/EP4635481A3/en active Pending
- 2019-09-27 US US17/250,952 patent/US20220370356A1/en active Pending
- 2019-09-27 WO PCT/US2019/053617 patent/WO2020072324A1/en not_active Ceased
- 2019-09-27 CN CN202410415224.2A patent/CN118307422A/zh active Pending
- 2019-09-27 DK DK19789841.4T patent/DK3860561T3/da active
- 2019-09-27 ES ES23157471T patent/ES3046484T3/es active Active
- 2019-09-27 CN CN201980077559.5A patent/CN113164379B/zh active Active
- 2019-09-27 AU AU2019351809A patent/AU2019351809C1/en active Active
- 2019-09-27 CA CA3114435A patent/CA3114435A1/en active Pending
-
2023
- 2023-11-14 JP JP2023193747A patent/JP7747712B2/ja active Active
-
2025
- 2025-07-24 AU AU2025208491A patent/AU2025208491A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020072324A5 (enExample) | ||
| CA2891911C (en) | Improved nucleic acid lipid particle formulations | |
| JP5475753B2 (ja) | 核酸送達用の脂質製剤 | |
| EP3201338B1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| US9701623B2 (en) | Di-aliphatic substituted pegylated lipids | |
| US9415109B2 (en) | Stable non-aggregating nucleic acid lipid particle formulations | |
| JP5977394B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| JP2017536092A5 (enExample) | ||
| EP2416652B1 (en) | Methods of delivering oligonucleotides to immune cells | |
| JP2015500835A5 (enExample) | ||
| JP6592458B2 (ja) | カチオン性脂質 | |
| AU2016210739A1 (en) | Biodegradable lipids for the delivery of active agents | |
| JP2011516094A5 (enExample) | ||
| CN102361650A (zh) | 用于递送治疗剂的新型脂质和组合物 | |
| JP2011507534A5 (enExample) | ||
| CA3123595A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| US20240115730A1 (en) | Tissue-specific nucleic acid delivery by 1,2-dioleoyl-3-trimethylammonium-propane (dotap) lipid nanoparticles | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| JP2024516152A (ja) | 混合カチオン性脂質粒子による組織特異的核酸送達 | |
| CN110022895A (zh) | 用于治疗乙型肝炎的治疗组合物和方法 | |
| US20220184113A1 (en) | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | |
| WO2025256540A1 (en) | Compositions and method for targeted gene delivery | |
| WO2024199144A1 (en) | Novel reagent for mitigating lnp toxicity | |
| EP4047094A1 (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| HK1234102B (en) | Compositions and methods for silencing hepatitis b virus gene expression |